Abstract
Data for ten European countries which provide detailed distribution of COVID-19 cases by sex and age show that among people of working age, women diagnosed with COVID-19 substantially outnumber infected men. This pattern reverses around retirement: infection rates among women fall at age 60-69, resulting in a cross-over with infection rates among men. The relative disadvantage of women peaks at ages 20-29, whereas the male disadvantage in infection rates peaks at ages 70-79. The elevated infection rates among women of working age are likely tied to their higher share in health- and care-related occupations. Our examination also suggests a link between women’s employment profiles and infection rates in prime working ages. The same factors that determine women’s higher life expectancy account for their lower fatality and higher male disadvantage at older ages.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Zuzanna Brzozowska's work on this manuscript has been supported by Operational Programme Research, Development and Education - Project MSCAfellow2@MUNI (CZ.02.2.69/0.0/0.0/18_070/0009846). All the other authors received no funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our work deals with official and publicly available demographic data and does not require any IRB and/or ethics committee approval-.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this work are official country data that are publicly available and are also explicitly detailed in the supplementary files and tables attached.
